Solara Active Pharma Sciences Limited (SOLARA) - Total Liabilities
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has total liabilities worth Rs10.36 Billion INR (≈ $112.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Solara Active Pharma Sciences Limited annual equity growth to track the company's year-over-year net asset growth rate.
Solara Active Pharma Sciences Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Solara Active Pharma Sciences Limited to measure how efficiently the company converts operating cash flow to free cash.
Solara Active Pharma Sciences Limited Competitors by Total Liabilities
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mkango Resources Ltd
V:MKA
|
Canada | CA$13.35 Million |
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
USA | $8.40 Million |
|
Kwong Lung Enterprise Co Ltd
TWO:8916
|
Taiwan | NT$5.16 Billion |
|
Nasmed Ozel Saglik Hizmetleri Ticaret AS
IS:EGEPO
|
Turkey | TL303.09 Million |
|
Nextgreen Global Bhd
KLSE:7241
|
Malaysia | RM245.65 Million |
|
Hot Chili Ltd
AU:HCH
|
Australia | AU$3.60 Million |
|
ThinTech Materials Technology Co Ltd
TWO:3663
|
Taiwan | NT$2.01 Billion |
|
Havilah Resources Ltd
AU:HAV
|
Australia | AU$1.69 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Solara Active Pharma Sciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Solara Active Pharma Sciences Limited market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Solara Active Pharma Sciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual total liabilities of Solara Active Pharma Sciences Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs11.35 Billion ≈ $122.74 Million |
-19.76% |
| 2024-03-31 | Rs14.14 Billion ≈ $152.96 Million |
+1.27% |
| 2023-03-31 | Rs13.97 Billion ≈ $151.04 Million |
-1.49% |
| 2022-03-31 | Rs14.18 Billion ≈ $153.33 Million |
+38.89% |
| 2021-03-31 | Rs10.21 Billion ≈ $110.40 Million |
-3.99% |
| 2020-03-31 | Rs10.63 Billion ≈ $114.99 Million |
+6.35% |
| 2019-03-31 | Rs10.00 Billion ≈ $108.12 Million |
-5.06% |
| 2018-03-31 | Rs10.53 Billion ≈ $113.89 Million |
+31911263.64% |
| 2017-03-31 | Rs33.00K ≈ $356.88 |
-- |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more